In vivo activity of the dual SYK/FLT3 inhibitor TAK-659 against pediatric acute lymphoblastic leukemia xenografts.
Keira HughesKathryn EvansEric Jay EarleyChristopher M SmithStephen W EricksonTim StearnsVivek M PhilipSteven B NeuhauserJeffrey H ChuangEmily L JocoyCarol J BultBeverly A TeicherMalcolm A SmithRichard B LockPublished in: Pediatric blood & cancer (2023)
TAK-659 exhibited low to moderate single-agent in vivo activity against pediatric ALL PDXs representative of diverse subtypes.